Reuters logo
BRIEF-Cell Therapeutics jumps in premarket after opaxiotm gets orphan drug designation
October 2, 2012 / 11:50 AM / 5 years ago

BRIEF-Cell Therapeutics jumps in premarket after opaxiotm gets orphan drug designation

NEW YORK, Oct 2 (Reuters) - Cell Therapeutics Inc : * Jumps 23.3 percent to $2.75 in premarket after opaxiotm gets orphan drug designation from U.S. Food and Drug Administration for malignant brain cancer

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below